IC‐P‐183: Reproducibility of intracranial and hippocampal volume quantification at 1.5T and 3T MRI: Application to ADNI I

Roche, Florent; Singh, Baljeet; Schaerer, Joël; Belaroussi, Boubakeur; Gouttard, Sylvain; Istace, Audrey; Yu, Hui Jing; Fletcher, Evan; Bracoud, Luc; Pachaï, Chahin; DeCarli, Charles

doi:10.1016/j.jalz.2013.05.180

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Companies that provide imaging services for clinical trials, such as Bioclinica [12–15] (recently merged with SYNARC [16–19]), IXICO, and Lilly [20] have used ADNI data to develop and validate their image quantification methods. For example, the learning embeddings for atlas propagation technology for repeated automated hippocampal volumetry was developed by ADNI researchers at Imperial College, London, based in part on de novo analyses of ADNI data [21,22], before being licensed to IXICO [23].…”

Section: Impacts Of Adnimentioning

confidence: 99%

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Weiner

Veitch

Aisen

et al. 2015

Alzheimer's & Dementia

214

166

View full text Add to dashboard Cite

Introduction The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer’s disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson’s disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

show abstract

Section: Impacts Of Adnimentioning

confidence: 99%

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Weiner

Veitch

Aisen

et al. 2015

Alzheimer's & Dementia

214

166

View full text Add to dashboard Cite

show abstract

“…Previous studies found that while most of the brain was identically classified at the two field strengths, there were some regional differences observed 61 . Others have reported highly reproducible volumetric data in adults with AD and controls, scanned on 1.5T and 3T scanners 62 . Upon closer investigation when comparing datasets acquired on 1.5 T and 3T scanners, we were able to conclude that there were no discernible differences in volumetric data.…”

Section: Discussionmentioning

confidence: 99%

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in-vivo fetal and neonatal MRI assessment

Patkee

Baburamani

Kyriakopoulou

et al. 2019

Preprint

View full text Add to dashboard Cite

Down Syndrome (DS) is the most frequent genetic cause of intellectual disability with a wide spectrum of neurodevelopmental outcomes. At present, the relationship between structural brain morphology and the spectrum of cognitive phenotypes in DS, is not well understood. This study aimed to quantify development of the fetal and neonatal brain in DS using dedicated, optimised and motion-corrected invivo magnetic resonance imaging (MRI). We detected deviations in development and altered regional brain growth in the fetus with DS from 21 weeks' gestation, when compared to age-matched controls.Reduced cerebellar volume was apparent in the second trimester with significant alteration in cortical growth becoming evident during the third trimester. Developmental abnormalities in the cortex and cerebellum are likely substrates for later neurocognitive impairment, and ongoing studies will allow us to confirm the role of antenatal MRI as an early biomarker for subsequent cognitive ability in DS. In the era of rapidly developing technologies, it is hoped that the results of this study will assist counselling for prospective parents.

show abstract

IC‐P‐183: Reproducibility of intracranial and hippocampal volume quantification at 1.5T and 3T MRI: Application to ADNI I

Cited by 2 publications

References 0 publications

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in-vivo fetal and neonatal MRI assessment

Contact Info

Product

Resources

About